

For the period from 01/01/2025 to 30/6/2025

For the period from 01/01/2025 to 30/6/2025



TABLE OF CONTENTS

CONTENTS	PAGES
BOARD OF GENERAL DIRECTORS' REPORT	02 - 03
REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION	04 - 05
INTERIM BALANCE SHEET	06 - 07
INTERIM INCOME STATEMENT	08
INTERIM CASH FLOW STATEMENT	09
NOTES TO THE INTERIM FINANCIAL STATEMENTS	10 - 31

BOARD OF GENERAL DIRECTORS' REPORT

The members of the Board of General Directors of Central Pharmaceutical Joint Stock Company No2 (hereinafter referred to as "the Company") presents this Report together with the Company's reviewed Interim Financial Statements for the period from 01/01/2025 to 30/6/2025.

Board of Management and Board of General Directors

Members of Board of Management and Board of General Directors who held the Company during the period from 01/01/2025 to 30/6/2025 and to the date of this report, include:

Board of Management

Mr. Cao Tien Dung	Chairman (Appointed on April 21, 2025)
Mr. Nguyen Tien Duc	Chairman (Resigned on April 21, 2025)
Mr. Le Tien Dung	Vice Chairman
Mr. Cao Minh Phuong	Vice Chairman (Appointed on April 21, 2025)
Mr. Cao Quang Hung	Member (Resigned on April 21, 2025)
Mr. Le Hoang Phong	Member (Appointed on April 21, 2025)
Mr. Nguyen Thanh Tung	Member
Mr. Cao Viet Hung	Member (Appointed on April 21, 2025)
Mrs. Cao Thuy Tien	Member (Appointed on April 21, 2025)

Board of General Directors

Mr. Le Tien Dung	General Director
Mr. Phan Tri Dung	Deputy General Director
Mr. Cao Tien Dung	Deputy General Director
Mr. Nguyen Thanh Tung	Deputy General Director

Respective responsibilities of Board of General Directors

The Board of General Directors of the Company is responsible for preparing Interim Financial Statements which give a true and fair view of the financial position, and results of operations and cash flows of the Company in the period, in accordance with Vietnamese Accounting Standards, corporate accounting system and legal regulations relating to the preparation and presentation of the Interim Financial Statements. In the preparation of these Interim Financial Statements, Board of General Directors is required to:

- Select suitable accounting policies and then consistently apply them;
- Make judgments and estimates that are reasonable and prudent;
- State whether appropriate accounting standards are respected or any application of material misstatements needs to be disclosed and justified in Interim Financial Statements;
- Prepare the Interim Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business; and

BOARD OF GENERAL DIRECTORS' REPORT

(continued)

- Design and implement an effective internal control system for the purpose of properly preparing and presenting the Interim Financial Statements so as to minimize risks and frauds.

The Board of General Directors is responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and that the Interim Financial Statements comply with Vietnamese Accounting Standards, corporate accounting system and legal regulations relating to the preparation and presentation of the Interim Financial Statements. The Board of General Directors is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of frauds and other irregularities.

The Board of General Directors confirms that the Company has complied with the above requirements in preparing these Interim Financial Statements.

For and on behalf of the Board of General Directors,

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2



Le Tien Dung (*Power of Attorney No. 97/UQ-DPTU2 dated April 22, 2025*)

General Director

Hanoi, August 11, 2025

No. 1208.01 - 25/BC-TC/VAE

Hanoi, August 12, 2025

**REPORT ON REVIEW OF
INTERIM FINANCIAL INFORMATION**

**To: The Shareholders
 The Board of Management and Board of General Directors
 Central Pharmaceutical Joint Stock Company No2**

We have reviewed the accompanying Interim Financial Statements of Central Pharmaceutical Joint Stock Company No2 (hereinafter referred to as "the Company"), *prepared on August 11, 2025, from page 06 to page 31*, which comprises: Interim Balance Sheet as at 30/6/2025, Interim Income Statement, Interim Cash Flow Statement for the period then ended and Notes to the Interim Financial Statements.

The Board of General Directors' responsibility

Board of General Directors of the Company is responsible for the preparation and fair presentation of these Interim Financial Statements in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations relating to the preparation and presentation of the Interim Financial Statements and for such internal control as Board of Directors determines is necessary to enable the presentation of Interim Financial Statements that are free from material misstatements whether due to fraud or error.

Auditors' responsibility

Our responsibility is to express a conclusion on these Interim Financial Statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagement (VSRE) 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity. Because of the matters described in the "Basis for Disclaimer of Conclusion" paragraph, however we were not able to obtain sufficient appropriate audit evidence to provide a basis for a conclusion of the Interim Financial Statements.

Basis for Disclaimer of Conclusion

The Company had recorded an increase in other income from the amount of support received according to the Minutes of Agreement on the transfer of shares at Binh An Developed Investment Joint Stock Company of the Viet Land Corporation to determine the business results in the years from 2010 to 2016 with a value of VND 99,600,000,000. As of 30/6/2025, we have not been provided with the Company's records and documents related to the completion of the procedures for transferring the above shares. Therefore, we cannot assess the impact of this issue on the Company's Interim Financial Statements for the period from January 1, 2025 to June 30, 2025.

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

(continued)

As presented in Note V.2, Notes to the Interim Financial Statements, the Company has an investment in another entity - Binh An Development Investment Joint Stock Company with a carrying value of VND 93,600,000,000 as of June 30, 2025 (VND 93,600,000,000 as of January 1, 2025). The Company has not yet obtained the Financial Statements of the investment recipient as a basis for assessing the impairment of this investment as of June 30, 2025 and January 1, 2025. We have also not been able to obtain sufficient appropriate documentation related to the impairment of this investment. Therefore, we are unable to determine whether any adjustments to these figures are necessary.

Disclaimer of Conclusion

Because of the importance of the matter described in the "Basis for Disclaimer of Conclusion" paragraph, we have not been able to obtain sufficient appropriate audit evidence to provide a basis for a conclusion of the Interim Financial Statements. Accordingly, we do not express a conclusion on the accompanying Interim Financial Statements for the period ended June 30, 2025 of the Company.



Pham Thanh Ngoc

Deputy General Director

Audit Practice Registration Certificate:

No. 1011-2023-034-1

For and on behalf of

VIETNAM AUDITING AND EVALUATION CO., LTD

2025
CÔNG
TRÁCH NHIỆP
KIỂM TOÁN VÀ
ĐỊNH GIÁ
VIỆT
NAM

Form B 01a - DN

INTERIM BALANCE SHEET

As at 30/6/2025

Unit: VND

ASSETS	Codes	Notes	30/6/2025	01/01/2025
A. CURRENT ASSETS	100		144,624,904,787	129,841,539,917
I. Cash and cash equivalents	110		9,822,588,052	5,053,168,373
1. Cash	111	V.1.	9,822,588,052	5,053,168,373
II. Short-term financial investments	120		-	-
III. Short-term receivables	130		83,891,103,345	76,690,595,733
1. Short-term trade receivables	131	V.3.	30,452,535,072	22,152,834,582
2. Advances to suppliers	132	V.4.	952,778,891	913,567,035
3. Other short-term receivables	136	V.5.	57,097,273,577	58,235,678,311
4. Provision for short-term doubtful debts	137		(4,611,484,195)	(4,611,484,195)
IV. Inventories	140	V.7.	50,329,456,545	47,610,369,449
1. Inventories	141		50,329,456,545	47,610,369,449
V. Other short-term assets	150		581,756,845	487,406,362
1. Short-term prepayments	151	V.11.	161,989,945	160,618,558
2. Value added tax deductibles	152		329,040,400	257,777,679
3. Taxes and receivables from the State budget	153	V.14.	90,726,500	69,010,125
B. NON-CURRENT ASSETS	200		301,465,938,104	312,791,806,940
I. Long-term receivables	210		72,240,000,000	72,240,000,000
1. Other long-term receivables	216	V.5.	72,240,000,000	72,240,000,000
II. Fixed assets	220		121,174,958,743	132,236,602,153
1. Tangible fixed assets	221	V.9.	121,174,958,743	132,236,602,153
- Historical cost	222		289,655,763,230	289,655,763,230
- Accumulated depreciation	223		(168,480,804,487)	(157,419,161,077)
2. Intangible fixed assets	227	V.8.	-	-
- Historical cost	228		810,751,750	810,751,750
- Accumulated amortization	229		(810,751,750)	(810,751,750)
III. Investment property	230		-	-
IV. Long-term assets in progress	240		76,805,661	76,805,661
1. Construction in progress	242	V.10.	76,805,661	76,805,661
V. Long-term financial investments	250		93,960,000,000	93,960,000,000
1. Investments into other entities	253	V.2.	93,960,000,000	93,960,000,000
VI. Other long-term assets	260		14,014,173,700	14,278,399,126
1. Long-term prepayments	261	V.11.	14,014,173,700	14,278,399,126
TOTAL ASSETS (270=100+200)	270		446,090,842,891	442,633,346,857

(The notes from page 10 to page 31 are an integral part of these Interim Financial Statements)

Form B 01a - DN

INTERIM BALANCE SHEET

As at 30/6/2025

(continued)

Unit: VND

RESOURCES	Codes	Notes	30/6/2025	01/01/2025
C - LIABILITIES	300		368,114,813,629	361,660,487,896
I. Current liabilities	310		274,154,813,629	267,700,487,896
1. Short-term trade payables	311	V.12.	28,074,033,467	19,658,618,096
2. Short-term advances from customers	312	V.13.	16,009,610,667	18,990,940,376
3. Taxes and amounts payable to the State budget	313	V.14.	54,002,656,224	54,006,314,179
4. Payables to employees	314		2,311,070,829	3,332,236,406
5. Short-term accrued expenses	315	V.15.	42,097,541,942	38,669,880,463
6. Other current payables	319	V.17.	28,559,268,414	30,861,866,290
7. Short-term loans and obligations under finance leases	320	V.16.	102,815,578,312	101,895,578,312
8. Bonus and Welfare funds	322		285,053,774	285,053,774
II. Non-current liabilities	330		93,960,000,000	93,960,000,000
1. Other long-term payables	337	V.17.	93,960,000,000	93,960,000,000
D OWNER'S EQUITY	400		77,976,029,262	80,972,858,961
I. Owner's equity	410	V.18.	77,800,739,262	80,797,568,961
1. Owner's contributed capital	411		200,000,000,000	200,000,000,000
- Ordinary shares carrying voting rights	411a		200,000,000,000	200,000,000,000
2. Capital surplus	412		4,902,500,000	4,902,500,000
3. Development and investment fund	418		3,267,017,189	3,267,017,189
4. Other owners' funds	420		249,948,734	249,948,734
5. Retained earnings	421		(130,618,726,661)	(127,621,896,962)
- Retained earnings accumulated to the prior year end	421a		(127,621,896,962)	(122,067,787,967)
- Retained earnings of current period	421b		(2,996,829,699)	(5,554,108,995)
II. Other resources and funds	430		175,290,000	175,290,000
1. Subsidised funds	431	V.19.	175,290,000	175,290,000
TOTAL RESOURCES (440=300+400)	440		446,090,842,891	442,633,346,857

Hanoi, August 11, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director

Dinh Thi Minh Huong

Nguyen Thi Dieu Thuy

Le Tien Dung

(The notes from page 10 to page 31 are an integral part of these Interim Financial Statements)

Form B 02a - DN

INTERIM INCOME STATEMENT
For the period from 01/01/2025 to 30/6/2025

Unit: VND

Items	Codes	Notes	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
1. Gross revenue from goods sold and services rendered	01	VI.1.	105,616,856,344	104,788,772,242
2. Revenue deductions	02	VI.2.	1,445,463,500	194,447,068
3. Net revenue from goods sold and services rendered (10=01-02)	10		104,171,392,844	104,594,325,174
4. Cost of sales	11	VI.3.	91,674,849,779	93,371,246,963
5. Gross profit from goods sold and services rendered (20=10-11)	20		12,496,543,065	11,223,078,211
6. Financial income	21	VI.4.	15,775,569	3,293,054
7. Financial expenses	22	VI.5.	6,113,635,670	6,132,819,162
Where: Interest expense	23		6,039,825,973	5,872,076,668
8. Selling expenses	25	VI.6.	1,672,628,875	1,676,047,711
9. General and administration expenses	26	VI.6.	7,512,265,507	6,129,200,703
10. Operating profit {30=20+(21-22)-(25+26)}	30		(2,786,211,418)	(2,711,696,311)
11. Other income	31	VI.7.	-54,112,760	1,216,421,501
12. Other expenses	32	VI.8.	264,731,041	262,806,353
13. Profit from other activities (40=31-32)	40		(210,618,281)	953,615,148
14. Accounting profit before tax (50=30+40)	50		(2,996,829,699)	(1,758,081,163)
15. Current corporate income tax expense	51	VI.9.	-	-
16. Deferred corporate income tax expenses	52		-	-
17. Net profit after corporate income tax (60=50-51-52)	60		(2,996,829,699)	(1,758,081,163)
18. Basic earning per share	70	VI.11.	(149.84)	(87.90)

Hanoi, August 11, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director



Dinh Thi Minh Huong



Nguyen Thi Dieu Thuy



Le Tien Dung

(The notes from page 10 to page 31 are an integral part of these Interim Financial Statements)

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2 INTERIM FINANCIAL STATEMENTS

Address: No. 9 Tran Thanh Tong Street, Hai Ba Trung Ward,
Hanoi, Vietnam

For the period from 01/01/2025 to 30/6/2025

Form B 03 - DN

INTERIM CASH FLOW STATEMENT

(Under direct method)

For the period from 01/01/2025 to 30/6/2025

Unit: VND

Items	Codes	Notes	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
I. Cash flow from operating activities				
1. Revenue from sales and services and other income	01		94,187,684,636	87,720,181,299
2. Payments to suppliers of goods and services	02		(67,676,835,281)	(67,198,626,533)
3. Cash paid to employees	03		(11,954,560,153)	(10,503,493,190)
4. Paid loan interest	04		(4,316,260,000)	(1,568,191,716)
5. Other cash inflows from operating activities	06		1,053,699,272	120,000,000
6. Other cash outflows from operating activities	07		(7,449,115,514)	(7,789,768,612)
<i>Net cash flow used in operating activities</i>	20		3,844,612,960	780,101,248
II. Cash flow from investing activities				
1. Interest earned, dividends and received profits	27		4,806,719	2,994,254
<i>Net cash flow used in investing activities</i>	30		4,806,719	2,994,254
III. Cash flow from financing activities				
1. Proceeds from borrowing	33		920,000,000	250,000,000
2. Prepayment of borrowing	34		-	(100,000,000)
<i>Net cash flow from financing activities</i>	40		920,000,000	150,000,000
Net increase/decrease in cash (50 = 20+30+40)	50		4,769,419,679	933,095,502
Cash and cash equivalents at the beginning of the period	60		5,053,168,373	3,584,348,015
Effect of changes in foreign exchange rates	61		-	-
Cash and cash equivalents at the end of the period (70 = 50+60+61)	70	V.1	9,822,588,052	4,517,443,517

Hanoi, August 11, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2

Prepared by

Chief Accountant

General Director

Dinh Thi Minh Huong

Nguyen Thi Dieu Thuy



Le Tien Dung

(The notes from page 10 to page 31 are an integral part of these Interim Financial Statements)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)

I. Operational characteristics of enterprise**1. Structure of ownership**

Central Pharmaceutical Joint Stock Company No2 (hereinafter referred to as “the Company”) is an independent economic unit, established and operating under Business Registration Certificate No. 0100109113 issued by the Hanoi Department of Planning and Investment on March 3, 2005. The Company has made 17 times of changed in its Business Registration Certificate.

Under the 17 amended Business Registration Certificate No. 0100109113 dated 25/4/2025 on change legal representative, due to the charter capital is **VND 200,000,000,000** *(Two hundred billion Vietnamese dong)*.

Share of the Company are being traded on the UPCOM with the trading code DP2.

2. Operating industry

The company operates in the field of pharmaceutical production and trading.

3. Principal activities

- Wholesale of other household items (Buying and selling personal and household items; business: medicinal materials, pharmaceutical chemicals, essential oils, contemporary medicine, oriental medicine, cosmetics, nutritional foods);
- Wholesale of machinery, equipment and others spare parts (Buying and selling machinery, equipment and spare parts; business: medical machinery and equipment; machinery, equipment, packaging for the production of contemporary medicine, oriental medicine, cosmetics, nutritional foods);
- Consultancy and technology transfer services in the pharmaceutical sector focus on scientific, technical, and professional activities that are not classified elsewhere;
- Real estate business, land use rights belonging to the owner, user or rent (Real estate business, renting houses, offices, warehouses, yards).

The Company's Head Office: No. 9 Tran Thanh Tong Street, Hai Ba Trung Ward, Hanoi, Vietnam.

4. Normal production and business cycle

The Company's normal period of production and business cycle is carry out for a time period of 12 months or less.

5. Disclosure of information comparability in the Interim Financial Statements

The respective information and figures presented in the Interim Financial Statements of the Company for the period from 01/01/2025 to 30/6/2025 are comparative.

6. Number of employees

The number of employees as at June 30, 2025 is 167 (as at December 31, 2024 is 170).

II. Accounting period and currency used in accounting**1. Accounting period**

The Company's accounting period begins on 01/01 and ends on 31/12 every year.
These Interim Financial Statements are prepared for the period from 01/01/2025 to 30/6/2025.

2. Currency used in accounting

The currency used in accounting is Vietnam dong (“VND”) accounted under the principle of historical cost, in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and the legal regulations related to the preparation and presentation of Interim Financial Statements.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***III. Applied accounting regime and standards****1. Applied accounting regime and standards**

The Company applies Vietnamese Accounting Standards and accounting regime for enterprises promulgated under Circular No. 200/2014/TT-BTC dated December 22, 2014 of the Ministry of Finance guiding the corporate accounting system and Circular No. 53/2016/TT-BTC dated March 21, 2016 of the Ministry of Finance amending some articles of Circular No. 200/2014/TT-BTC.

2. Statement on compliance to Accounting Standards and Accounting regime

The Company's Interim Financial Statements are prepared and presented in accordance with Vietnamese Accounting Standards and current Vietnamese Accounting regime for enterprises and the laws and regulations in relation to the preparation and presentation of Interim Financial Statements.

IV. Summary of significant accounting policies**1. Foreign exchange rates applied in accounting**

Exchange rates for translating transactions denominated in foreign currencies in the period are translated at exchange rates ruling at transaction date by the Joint Stock Commercial Bank for Investment and Development of Vietnam and the Joint Stock Commercial Bank for Industry and Trade of Vietnam.

The exchange rate when re-evaluating foreign currency items at the time of preparing the Interim Financial Statement is the exchange rate announced by the Joint Stock Commercial Bank for Investment and Development of Vietnam and the Joint Stock Commercial Bank for Industry and Trade of Vietnam at the time of preparing the Interim Financial Statement, in which:

- The exchange rate when revaluating foreign currency items classified as assets is the buying rate of the Joint Stock Commercial Bank for Investment and Development of Vietnam and the Joint Stock Commercial Bank for Industry and Trade of Vietnam at the time of preparing the Interim Financial Statement.

- The exchange rate when re-evaluating foreign currency items classified as liabilities is the selling rate of the Joint Stock Commercial Bank for Investment and Development of Vietnam and the Joint Stock Commercial Bank for Industry and Trade of Vietnam at the time of preparing the Interim Financial Statement.

2. Estimates

The preparation of Interim Financial Statements in conformity with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to financial reporting requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the Interim Financial Statements and the reported amounts of revenues and expenses during the financial year. Although these accounting estimates are based on the Management's best knowledge, actual results may differ from those estimates.

3. Principle of recognizing cash

Cash include cash on hand, demand deposits highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

4. Accounting principle for financial investments***Equity investments in other entities***

Equity investments in other entities represent the Company's investments in Binh An Developed Investment Joint Stock Company, records investments in equity instruments which the Company has no control, joint control or significant influence.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)

Equity investments in other entities are carried at historical cost, including purchase price or capital contribution plus costs directly related to investment activities.

Provision for losses on investments in equity instruments of other entities is made at the time of preparing Interim Financial Statements when the investments have a decline compared to the original price, the Company makes provisions as follows:

- For investments whose fair value cannot be determined at the reporting date, provisions are made at an amount equal to the difference between the actual capital contributions of the parties at other entities and the actual equity multiplied by the Company's capital contribution ratio compared to the total actual capital contributions of the parties at other entities.

Increase, decrease in the provision for investment in other entities that must be appropriated at the closing date of preparing Interim Financial Statements is recorded in financial expenses.

As at June 30, 2025, the Company has not considered making provisions for equity investments in other entities.

5. Accounting principle of receivables

Receivables present the amounts recoverable from customers and are stated at book value less provisions for doubtful debts. Receivables are classified on the following principle:

- Trade accounts receivable consist of receivables with their commercial nature arising from transactions with their purchasing-selling nature between the Company and buyers who are independent entities from the Company.
- Other receivables consist of receivables with their non-commercial nature, not related to transactions with their purchasing-selling nature.

Receivables are monitored in detail for each subject and the maturity of amounts receivable and other elements according to the management demand of enterprise.

Provision for doubtful debts is made receivables that are overdue in the economic contracts, contractual commitments or debt repayment commitments that the enterprise has repeatedly requested but has not yet recovered or when the debtor is in dissolution, in bankruptcy or is experiencing similar difficulties and so may be unable to repay the debt.

Increases and decreases in the balance of the provision for doubtful debts that must be set up at the closing date of the Interim Financial Statements are recorded in business management expenses.

As at June 30, 2025, the Company has not considered making provisions for doubtful debts.

6. Principle for recognizing inventories

Inventories are recognized at the lower price between historical cost and net realizable value. Historical cost of inventories consists of expenses of acquisition, processing and other directly related expenses (if any) incurred to bring inventories to their present location and condition.

Net realizable value is determined as the estimated selling price of inventories during the normal business period minus the estimated costs to complete and necessary estimated costs to sell.

Value of inventories is determined under using the weighted average method and accounted for by perpetual method.

As at June 30, 2025, the Company had no inventories that need to make provision for devaluation.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***7. Principle for fixed asset recognition and depreciation****7.1 Principle for tangible fixed asset recognition and depreciation**

Tangible fixed assets are stated at cost, presented in the Interim Balance sheet under the items of historical cost, accumulated depreciation and carrying amount.

The cost of purchased tangible fixed assets comprise their purchase prices (excluding trade discount or other discount), taxes and any directly attributable costs of bringing the assets to their working condition for use.

Historical cost of fixed assets which are constructed by contractors includes value of completed and handover works, directly-related costs and stamp duty.

The historical cost of procured tangible fixed assets include actual price of tangible fixed assets which are self-constructed or self-made and their installation and commissioning expense.

The expenses incurred after the initial recognition of tangible fixed assets are recorded as the increases of historical cost of assets when these expenses are sure to increase economic benefits in the future. The incurred expenses which do not satisfy the above conditions are recognized into operating expenses in the period.

The Company applied straight-line depreciation method to tangible fixed assets. Tangible fixed assets are accounted and classified into groups by their nature and purpose of utilization in the Company's production and business operation, including:

<i>Type of fixed assets</i>	<i>Depreciation duration <years></i>
Building and architectural objects	10 - 25
Machinery, equipment	03 - 10
Transportation means	06 - 09
Managerial equipment, tools	03 - 10
Other fixed assets	03 - 10

Gains and losses resulting from sale or disposals of tangible fixed assets is the difference between profit from sales or disposals of assets and their residual values and is recognised in the Interim Income Statement.

7.2 Principle for intangible fixed asset recognition and amortization

Intangible fixed assets are stated at cost, presented in the Interim Balance sheet under the items of historical cost, accumulated amortization and carrying amount.

Historical cost of intangible fixed assets consists of their total purchase price of bringing the assets to their working condition for use. The costs arising after initial recognition of intangible fixed assets are recorded as production costs in the period excluding specific costs of a specific intangible asset, enabling an increase in the future economic benefits.

When an intangible fixed asset is sold or disposed, historical cost and accumulated amortization are written off and gain or loss from disposal is recognized into income or expense in the period.

Intangible assets of the Company is accounting software programs.

Software programs

Costs in relation to translation software programs are not an integral part of the relevant capitalized hardware. Historical costs of computer softwares is the whole expenditure paid by the Company until the softwares are put into use. Computer softwares are amortized on straight line basis within 04 years.

Gains and losses resulting from sale or disposals of intangible fixed assets is the difference between profit from sales or disposals of assets and their residual values and is recognised in the Interim Income Statement.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)

8. Principle for recognizing construction in progress

The Company's construction in progress is the investment cost for the construction of the project "Vinh Tuy construction project" and others, are carried out at cost. This cost includes the costs necessary to form the asset in accordance with the Company's accounting policy. Depreciation of these assets is applied in the same way as other assets, commencing when the assets are ready for use.

9. Accounting principles for business cooperation contracts

A business cooperation contract (BCC) means a cooperation contract between two or more venturers in order to carry out specific business activities, but it does not require establishment of a new legal entity. Those activities may be jointly controlled by the capital contributors under the joint venture agreement or controlled by one of several participating parties.

10. Principle for recognition and allocation of prepayments

Prepayments include land use rights with a term, land rental costs and industrial park infrastructure, factory repair costs, tools, supplies issued for use awaiting for allocation and other costs... which are expected to provide future economic benefits to the Company, capitalized in the form of prepaids.

Land use rights with a term, land rental costs and industrial park infrastructure are allocated to the Interim Income Statement using the straight-line method over the lease term.

Tools and supplies awaiting allocation, biocompatibility testing costs, factory repair costs awaiting allocation and other costs are considered to be able to provide future economic benefits to the Company. These costs are capitalized as prepayments and allocated to the Income Statement, using the straight-line method over a period of no more than 03 years.

11. Accounting principle for liabilities

Liabilities are amounts payable to suppliers and other subjects. Liabilities comprise trade accounts payable and other payables. Liabilities are not recorded at lower amounts than payment obligation.

- Trade accounts payable comprise of liabilities with their commercial nature arising from purchasing goods, services, assets and the suppliers are independent from buyers.

- Other amounts payable comprise amounts payable with their non-commercial nature, not related to transactions of purchasing, selling and supplying goods, services.

Liabilities are monitored by details of each item and due date. Foreign currency liabilities are revalued by the Company at the Commercial Bank where the Company regularly conducts transactions as at June 30, 2025.

12. Principle for recognizing loans

Loans are recognized on the basis of receipts, bank vouchers, loan agreement and loan contracts.

Loans are monitored by details of each item, due date and original currency.

13. Principle for recognition and capitalization of borrowing costs

Borrowing costs consist of loan interest and other costs that incurs in direct connection with the borrowings.

Borrowing costs are recognized into operation and production costs in the period.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)

14. Principle for recognizing accrued expense

Accrued expenses comprise interest payable, late interest and others, including actual expenses incurred in the reporting period but unpaid because no invoice was available or accounting documents are missing, being recognized in operating expenses of the reporting period.

Accrued expenses on production and business expenses in the period are calculated strictly with reasonable and reliable evidence on the expenses to be accrued in the period to ensure the accounting expenses payable to be accounted will match the actual costs incurred.

15. Principle for recognizing owner's equity

Capital investment of the Company's owners is recognized by owner's actual capital contribution.

Capital surplus is recognized as the difference between the issuance price and the par value of shares during the initial issuance, additional issuance, the difference between the reissuance price and the book value of treasury shares, and the equity component of convertible bonds upon maturity. Direct costs related to additional share issuance and the reissuance of treasury shares are deducted from capital surplus.

Retained earnings are the profit amounts from enterprise's business operation after deducting CIT expense this year and the retroactive adjustments due to changes in accounting policies and the retroactive adjustment of material misstatements in the previous years.

16. Principle and method of recognizing revenue

The Company's revenue includes revenue from goods sold, warehouse for rent, revenue from the sale of investments, dividends and interest from bank deposits.

Revenue from sales of goods and finished products

Revenue from selling goods, finished products is recognized upon simultaneously meeting the following five (5) conditions as follows:

- The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;
- The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- Turnover is determined with relative certainty. In case the contract specifies that buyers have the right to return goods or products that were bought under specific terms, the revenue is only recognized when these specific terms no longer exist and the buyers have no right to return goods or products (except for the case that customers can return goods as exchange to other goods or services);
- The Company gained or will gain economic benefits from the sale transaction; and
- It is possible to determine the costs related to the goods sale transaction.

Interest income

Interest amounts are recognized on accrual basis, being determined on balances of deposits and actual interest rate in the period.

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***17. Principle and method of recognizing deductions**

Sales returns are products that have been sold but are returned by customers because they do not meet quality, type or specification standards. Therefore, revenue from sales returns is a deduction from revenue generated during the period. At the end of the period, this revenue will be transferred to adjust the actual net revenue of that period.

18. Principle and method of recognizing financial expense

Financial expense recognized in Interim Income Statement is the total financial expense incurred in the period, without offset with revenue from financial income, including interest expenses, exchange rate difference and other financial expense.

19. Tax liabilities***Value added tax (VAT)***

The Company declares and calculates VAT under the guidelines of current value added tax law.

Corporate income tax

Corporate income tax presents the total amount of current tax payable.

Current tax payable is calculated on taxable profit in the period. Taxable income differs from net profit presented in the Income Statement because taxable income does not include assessable incomes or expenses or deductible one in other years (including losses carried forward, if any) and it further excludes items that are non-taxable or non-deductible.

The Company declares corporate income tax using the tax rate of 20% of taxable profit.

The determination of taxable income and tax currently payable is based on the current interpretation of tax regulations. However, these regulations are subject to periodic variation and its ultimate determination depends on the results of tax authorities' examination.

Other taxes

Other taxes are declared and paid to local tax authorities in accordance with the prevailing tax law in Vietnam.

20. Segment Reporting

A segment is a distinguishable component of the Company that is engaged either in providing related products or services (business segment) or in providing products or services within a particular economic environment (geographical segment) that is subject to risks and returns that are different from those of other business segments. The Board of General Directors believes that the Company's principal activities are the production and business of pharmaceutical products and that it operates mainly in one geographical department, which is Vietnam. Therefore, the Company does not present segment reports by business segment and by geographical area in accordance with Vietnamese Accounting Standard No. 28 - Segment reporting.

V. Additional information for items presented in the Interim Balance Sheet

1. Cash	30/6/2025	01/01/2025
	VND	VND
Cash on hand	281,561,790	594,457,069
Cash in bank	9,541,026,262	4,458,711,304
Total	9,822,588,052	5,053,168,373

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***2. Financial investments***Investments into other entities*

	30/6/2025 VND		01/01/2025 VND	
	Historical cost	Provision	Historical cost	Provision
Long-term				
Binh An Developed Investment JSC (i)	93,960,000,000	-	93,960,000,000	-
Total	93,960,000,000	-	93,960,000,000	-

(i) Investment pursuant to Investment Cooperation Contract No. 01/HTDT dated December 28, 2007, between Central Pharmaceutical Joint Stock Company No2 and Viet Land Corporation for the establishment of Binh An Developed Investment Joint Stock Company. The company has not yet obtained the investee's Financial Statements for the period from 01/01/2025 to 30/6/2025 as a basis for assessing the impairment of this investment. The company was unable to ascertain the fair value of this investment due to the lack of a transaction price and the insufficient information required for a proper valuation assessment. During the period, the Company didn't arise any transactions with Binh An Developed Investment Joint Stock Company.

3. Trade receivables

	30/6/2025 VND		01/01/2025 VND	
	Amount	Provision	Amount	Provision
Short-term				
Hoang Ha Commerce and Service JSC	1,708,855,306	-	103,977,224	-
Vinh Quang Independent Pharmacy	967,889,134	-	1,179,863,634	-
Tam Phat Pharmaceutical Trading JSC	2,579,620,873	-	2,431,803,708	-
Huong Viet Pharmaceutical JSC	781,713,775	-	2,361,553,219	-
Sapphire Pharmaceutical Co., Ltd	1,048,414,352	-	1,048,414,352	-
Eastern Europe Pharmaceutical JSC	4,291,644,622	-	1,067,988,892	-
Thien Dat Pharmaceutical JSC	1,790,703,551	-	559,412,371	-
An Phat Pharmaceutical Technology & Trading JSC	1,667,997,985	-	250,803,000	-
Sinh Phuc Pharmaceutical Technology and Trading Co.,Ltd	2,160,953,039	-	2,573,083,196	-
Others	13,454,742,435	(299,074,297)	10,575,934,986	(299,074,297)
Total	30,452,535,072	(299,074,297)	22,152,834,582	(299,074,297)

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***4. Advances to suppliers**

	30/6/2025	01/01/2025
	VND	VND
BMN Medical and Scientific Instrument Co.,Ltd	242,828,400	-
Inbiotech Limited	154,588,608	-
AQP Research and Control Pharmaceuticals JSC	123,852,400	-
Mediplantex National Pharmaceutical JSC	-	549,002,625
Others	431,509,483	364,564,410
Total	952,778,891	913,567,035

5. Other receivables

	30/6/2025		01/01/2025	
	VND		VND	
	Amount	Provision	Amount	Provision
a) Short-term	57,097,273,577	(4,312,409,898)	58,235,678,311	(4,312,409,898)
Advances	151,917,426	-	166,917,426	-
Nguyen Thuy Hang	35,000,000	-	35,000,000	-
Others	116,917,426	-	131,917,426	-
Mortgages, collaterals	751,277,512	-	937,656,060	-
Social insurance paid first	798,740,319	-	1,953,222,422	-
Other receivables	55,395,338,320	(4,312,409,898)	55,177,882,403	(4,312,409,898)
Binh An Developed Investment JSC (i)	49,600,314,938	-	49,600,314,938	-
Tran Bao Cuong	2,345,000,000	(2,345,000,000)	2,345,000,000	(2,345,000,000)
Others	3,450,023,382	(1,967,409,898)	3,232,567,465	(1,967,409,898)
b) Long-term	72,240,000,000	-	72,240,000,000	-
Other receivables	72,240,000,000	-	72,240,000,000	-
Nhat Minh Production Co.,Ltd (ii)	72,240,000,000	-	72,240,000,000	-
Total	129,337,273,577	(4,312,409,898)	130,475,678,311	(4,312,409,898)

(i) This is the land rent receivable of Binh An Developed Investment JSC at No. 9 Tran Thanh Tong, Hai Ba Trung Ward, Hanoi City from October 2012 to December 31, 2015, according to Ground Handover Minute No. 521 dated October 1, 2012 and Appendix 1 No. 525 dated October 3, 2012.

(ii) This is an investment under the business cooperation contract No. 10/2017NM-DTW2-VH dated May 10, 2017, Contract Appendix No. 101/2018/NM-DPTW2-VH dated September 6, 2018, and Contract Appendix No. 02/2023/NM-DTW2-VH dated January 9, 2023 on adjusting the term of business investment cooperation to December 31, 2024 to implement the Dai Mo low-rise housing construction investment project in Dai Mo, Nam Tu Liem, Hanoi and the Office Center for Lease Project at No. 15 The Giao, Hai Ba Trung, Hanoi with a total investment capital of VND 170 billion for the construction of the two above projects. According to the capital contribution agreement dated May 10, 2017, and the first capital contribution agreement amendment document dated September 5, 2018, between Viet Hien Development Company Limited, Central Pharmaceutical Joint Stock Company No2 and Nhat Minh Production Company Limited - Hanoi Branch, Central Pharmaceutical Joint Stock Company No2 accounts for 42.62% of the total investment capital, Nhat Minh Production Company Limited accounts for 26.84% of the total investment capital, Viet Hien Development Company Limited accounts for 30.54% of the total investment capital.

c) Other receivables from related parties: Details are presented in Note VIII.2

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)

6. Bad debts	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Recoverable amount	Cost	Recoverable amount
Total value of receivables, other receivables that are overdue or not overdue but difficult to recover				
<i>Trade receivables</i>	299,074,297	-	299,074,297	-
Southeast Asia	81,568,705	-	81,568,705	-
Pharmaceutical				
Others	217,505,592	-	217,505,592	-
<i>Other receivables</i>	4,312,409,898	-	4,312,409,898	-
Tran Bao Cuong	2,345,000,000	-	2,345,000,000	-
Nguyen Chi Dung	339,952,000	-	339,952,000	-
Pham Dang Khoa	139,200,000	-	139,200,000	-
Others	1,488,257,898	-	1,488,257,898	-
Total	4,611,484,195	-	4,611,484,195	-

7. Inventories	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Provision	Cost	Provision
Raw material	33,489,085,547	-	27,393,596,296	-
Tools and supplies	244,287,589	-	9,118,366	-
Work in progress	5,147,373,192	-	6,376,772,136	-
Finished goods	11,448,710,217	-	13,830,882,651	-
Total	50,329,456,545	-	47,610,369,449	-

8. Increases, decreases in intangible fixed assets

	Unit: VND	
	Accounting software	Total
<i>Historical cost</i>		
Balance as at 01/01/2025	810,751,750	810,751,750
Balance as at 30/6/2025	810,751,750	810,751,750
<i>Accumulated amortization</i>		
Balance as at 01/01/2025	810,751,750	810,751,750
Balance as at 30/6/2025	810,751,750	810,751,750
<i>Net book value</i>		
As at 01/01/2025	-	-
As at 30/6/2025	-	-

- The cost of intangible assets at the end of the period that have been fully depreciated but are still in use as at June 30, 2025 is VND 810,751,750 (As at December 31, 2024: VND 810,751,750)

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)

9. Increases, decreases of tangible fixed assets

Items	Building and structures	Machinery, equipment	Transportation means	Managerial equipment, tools	Others	Total
Historical cost						
Balance as at 01/01/2025	84,974,713,142	198,351,158,284	2,940,685,808	2,068,622,571	1,320,583,425	289,655,763,230
Balance as at 30/6/2025	84,974,713,142	198,351,158,284	2,940,685,808	2,068,622,571	1,320,583,425	289,655,763,230
Accumulated depreciation						
Balance as at 01/01/2025	30,656,066,423	121,983,541,845	2,875,086,392	1,076,978,034	827,488,383	157,419,161,077
Depreciation in the period	1,604,526,066	9,366,368,868	18,474,588	57,112,110	15,161,778	11,061,643,410
Balance as at 30/6/2025	32,260,592,489	131,349,910,713	2,893,560,980	1,134,090,144	842,650,161	168,480,804,487
Net book value						
As at 01/01/2025	54,318,646,719	76,367,616,439	65,599,416	991,644,537	493,095,042	132,236,602,153
As at 30/6/2025	52,714,120,653	67,001,247,571	47,124,828	934,532,427	477,933,264	121,174,958,743

- Historical cost of fixed assets that have been fully depreciated but are still in use as at June 30, 2025: VND 26,935,400,224 (As at December 31, 2024: VND 21,193,377,265).

- Closing net book value of tangible fixed assets used for mortgage, collateral to secure borrowing amounts as at June 30, 2025: VND 115,164,633,704 (As at December 31, 2024: VND 125,927,605,760)

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***10. Construction in progress**

	30/6/2025 VND	01/01/2025 VND
Vinh Tuy construction project	76,805,661	76,805,661
Total	76,805,661	76,805,661

11. Prepayments

	30/6/2025 VND	01/01/2025 VND
a) Short-term	161,989,945	160,618,558
Research expenses awaiting allocation	1,787,497	734,281
Other expenses awaiting for allocation	160,202,448	159,884,277
b) Long-term	14,014,173,700	14,278,399,126
Land use rights are limited in duration (*)	8,815,060,505	8,969,710,685
Land rental costs and infrastructure of Quang Minh Industrial Park	3,427,633,617	3,485,402,721
Factory repair costs awaiting allocation	290,205,166	392,630,545
Other expenses awaiting for allocation	1,481,274,412	1,430,655,175
Total	14,176,163,645	14,439,017,684

(*) The remaining value of the Land Use Rights with a term used to secure loans as at June 30, 2025, is VND 8,815,060,505 (As at December 31, 2024, it is VND 8,969,710,685).

12. Trade payables

	30/6/2025 VND		01/01/2025 VND	
	Historical cost	Amount payable	Historical cost	Amount payable
Short-term				
Aristopharma Limited	7,686,143,010	7,686,143,010	-	-
Van Son International Economic and Technical Cooperation Company	7,346,050,277	7,346,050,277	7,346,050,277	7,346,050,277
MI Pharma Private Limited	1,793,271,384	1,793,271,384	2,159,462,950	2,159,462,950
Pharbaco Central Pharmaceutical JSC No.1	521,487,707	521,487,707	1,473,575,740	1,473,575,740
Albios Lifesciences Private Limited	1,342,542,200	1,342,542,200	1,229,003,100	1,229,003,100
Toan Phuc Pharmaceutical Chemical Co.,Ltd	88,200,000	88,200,000	1,507,906,286	1,507,906,286
Others	9,296,338,889	9,296,338,889	5,942,619,743	5,942,619,743
Total	28,074,033,467	28,074,033,467	19,658,618,096	19,658,618,096

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***13. Advances from customers**

	30/6/2025 VND	01/01/2025 VND
<i>Short-term</i>		
Generic Pharmaceutical JSC	-	973,530,932
Southeast Asia Pharmaceutical and Medical Equipment JSC	3,926,890,075	1,518,956,641
Xuan Anh Pharmaceutical and Equipment Co.,Ltd	3,120,505,756	6,966,231,329
Minh An Pharmaceutical Technology Co.,Ltd	2,054,484,980	2,502,761,314
Capital Pharmacy JSC	368,336,710	1,374,059,046
Others	6,539,393,146	5,655,401,114
Total	16,009,610,667	18,990,940,376

14. Taxes and amounts payable to the State budget

	01/01/2025	Payable in the period	Paid in the period	Unit: VND 30/6/2025
<i>a) Payables</i>				
Value added tax	-	992,619,637	992,619,637	-
Import tax	-	992,619,637	992,619,637	-
Personal income tax	10,408,517	143,612,909	147,270,864	6,750,562
Housing tax, land rent	53,995,905,662	143,612,909	143,612,909	53,995,905,662
Other taxes	-	4,000,000	4,000,000	-
Total	54,006,314,179	2,276,465,092	2,280,123,047	54,002,656,224
<i>b) Receivables</i>				
VAT on imported goods	-	1,745,080,406	1,766,796,781	21,716,375
Corporate income tax	69,010,125	-	-	69,010,125
Total	69,010,125	1,745,080,406	1,766,796,781	90,726,500

15. Accrued expenses

	30/6/2025 VND	01/01/2025 VND
<i>Short-term</i>		
Advance payment of interest expenses and late payment of interest	42,086,841,942	38,583,040,463
Other accrued expenses	10,700,000	86,840,000
Total	42,097,541,942	38,669,880,463

INTERIM FINANCIAL STATEMENTS
For the period from 01/01/2025 to 30/6/2025

Form B 09a - DN

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2
Address: No. 9 Tran Thanh Tong Street, Hai Ba Trung Ward, Hanoi, Vietnam

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)

(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)

16. Loans and obligations under finance lease

	30/6/2025		In the period		01/01/2025	
	Amount	Amount able to be paid off	Increases	Decreases	Amount	Amount able to be paid off
a) Short-term	102,815,578,312	102,815,578,312	920,000,000	-	101,895,578,312	101,895,578,312
Short-term loans	8,300,000,000	8,300,000,000	920,000,000	-	7,380,000,000	7,380,000,000
Personal loan (*)	8,300,000,000	8,300,000,000	920,000,000	-	7,380,000,000	7,380,000,000
Cao Minh Phuong	2,880,000,000	2,880,000,000	-	-	2,880,000,000	2,880,000,000
Le Van Tien	1,000,000,000	1,000,000,000	-	-	1,000,000,000	1,000,000,000
Dinh Thi Minh Huong	720,000,000	720,000,000	720,000,000	-	-	-
Others	3,700,000,000	3,700,000,000	200,000,000	-	3,500,000,000	3,500,000,000
Long-term loans on due date	94,515,578,312	94,515,578,312	-	-	94,515,578,312	94,515,578,312
Vietnam Development Bank - Transaction Office 1 Branch (**)	94,515,578,312	94,515,578,312	-	-	94,515,578,312	94,515,578,312
Total	102,815,578,312	102,815,578,312	920,000,000	-	101,895,578,312	101,895,578,312

(*) Loans to employees in the Company are to supplement working capital with an interest rate of 8%/year, a loan term of less than 12 months.

(**) Loan from Vietnam Development Bank - Transaction Office 1 Branch under Contract No. 02/2007/HDTĐ dated November 15, 2007, amended contract No. 09.02.2007/HDDSD- NHPT.SGDI dated March 31, 2016, to invest in purchasing equipment and installation for the project "Investing in the construction of a pharmaceutical factory meeting GMP-WHO standards". This loan is secured by mortgaging assets formed from loan capital and land use rights and assets attached to the Company's land at Quang Minh Industrial Park, Quang Minh Commune, Me Linh District, Hanoi City. The loan interest rate is 9%/year, loan term is 18 years.

b) Loans with related parties: Details are presented in Note VIII.2

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***17. Other payables**

	30/6/2025 VND	01/01/2025 VND
a) Short-term	28,559,268,414	30,861,866,290
Trade Union Fee	915,491,055	1,345,941,665
Other payables	27,643,777,359	29,515,924,625
Dividends payable	107,755,846	107,755,846
Nhat Minh Production Company Limited Branch in Hanoi (i)	26,410,000,000	26,410,000,000
Others	1,126,021,513	2,998,168,779
b) Long-term	93,960,000,000	93,960,000,000
Other payables	93,960,000,000	93,960,000,000
Binh An Developed Investment Joint Stock Company (ii)	93,960,000,000	93,960,000,000
Total	122,519,268,414	124,821,866,290

(i) This is the amount payable according to Official Dispatch requesting working capital support No. 580/CV-DPTW2 dated December 10, 2018, of Central Pharmaceutical Joint Stock Company No2, Official Dispatch agreeing to support working capital dated December 20, 2018, loan without interest, no collateral, no term.

(ii) This is a loan from Binh An Developed Investment Joint Stock Company to reinvest in this Company.

c) Other payables with related parties: Details are presented in Note VIII.2

18. Owner's equity**a) Movement in owner's equity**

Items	Owner's contributed capital	Capital surplus	Retained earnings	Unit: VND Total
Balance as at 01/01/2024	200,000,000,000	4,902,500,000	(122,067,787,967)	82,834,712,033
Loss in previous year	-	-	(5,554,108,995)	(5,554,108,995)
Balance as at 31/12/2024	200,000,000,000	4,902,500,000	(127,621,896,962)	77,280,603,038
Loss this period	-	-	(2,996,829,699)	(2,996,829,699)
Balance as at 30/6/2025	200,000,000,000	4,902,500,000	(130,618,726,661)	74,283,773,339

b) Details of owner's equity contribution

	30/6/2025 VND	01/01/2025 VND
Vietnam Pharmaceutical Corporation - JSC	13,566,500,000	13,566,500,000
Viet Land Corporation	24,748,000,000	24,748,000,000
Saigon Handicraft Fine Art Export JSC	150,000,000,000	150,000,000,000
Others	11,685,500,000	11,685,500,000
Total	200,000,000,000	200,000,000,000

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***c) Capital transactions with owners, dividend distribution and shared profit**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Owners' contributed capital	200,000,000,000	200,000,000,000
Contribution at the beginning of the period	200,000,000,000	200,000,000,000
Contribution at the period end	200,000,000,000	200,000,000,000
Paid dividend, shared profit	-	-

d) Shares

	30/6/2025 Shares	01/01/2025 Shares
Number of shares registered for issue	20,000,000	20,000,000
Number of shares issued to the public	20,000,000	20,000,000
- Ordinary shares	20,000,000	20,000,000
Number of outstanding shares in circulation	20,000,000	20,000,000
- Ordinary shares	20,000,000	20,000,000
A common share has par value of VND 10,000 per share		

e) Funds of the Company

Items	01/01/2025	Increase in the period	Decrease in the period	Unit: VND 30/6/2025
Development and investment fund	3,267,017,189	-	-	3,267,017,189
Other owners' funds	249,948,734	-	-	249,948,734
Total	3,516,965,923	-	-	3,516,965,923

*** Purpose of appropriation and use of enterprise funds**

The enterprise's development investment fund is appropriated from the profit after corporate income tax and is used to supplement the Company's charter capital by investing in expanding the scale of production and business or in-depth investment of the enterprise. In accordance with the provisions of the Company's charter.

19. Subsidised funds	30/6/2025 VND	01/01/2025 VND
Funds remaining at the beginning of the period	175,290,000	175,290,000
Funding provided during the period	-	-
Career spending	-	-
Funds remaining at the end of the period	175,290,000	175,290,000
20. Off Interim Balance Sheet items	30/6/2025	01/01/2025
Foreign currencies		
USD bank deposit	1,194.27	1,207.47

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***VI. Additional information for items presented in the Interim Income Statement****1. Gross revenue from goods sold and services rendered**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Revenue from sales of goods	338,604,571	123,829,994
Revenue from sales of finished products	105,278,251,773	104,664,942,248
Total	105,616,856,344	104,788,772,242

2. Revenue deductions

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Sales Returns	1,445,463,500	194,447,068
Total	1,445,463,500	194,447,068

3. Cost of sales

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Cost of goods sold	322,207,506	123,757,176
Cost of finished goods sold	91,352,642,273	93,247,489,787
Total	91,674,849,779	93,371,246,963

4. Financial income

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Interest on bank deposits and margin interest	4,806,719	2,994,254
Exchange rate difference interest arises during the period	10,968,850	298,800
Total	15,775,569	3,293,054

5. Financial expenses

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Financial expenses		
Interest expense	6,039,825,973	5,872,076,668
Interest on late payment	-	87,397,416
Exchange rate difference loss arising during the period	73,809,697	173,345,078
Total	6,113,635,670	6,132,819,162

b) Financial expenses with related parties: Details are presented in Note VIII.2

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***6. Selling expenses and general and administration expenses**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Selling expenses incurred in the period	1,672,628,875	1,676,047,711
Labour cost	1,178,466,486	1,022,722,788
Cost of materials and packaging	3,339,466	2,132,162
Depreciation of fixed assets	18,474,588	18,474,588
Others expenses	472,348,335	632,718,173
b) General administration expenses incurred in the period	7,512,265,507	6,129,200,703
Labour cost	3,272,623,765	2,897,039,646
Tool costs	140,478,525	400,150,625
Fixed asset depreciation	175,280,166	176,462,031
Taxes, fees and charges	387,082,751	341,196,512
Out-sourced services	142,666,787	-
Other monetary expenses	3,394,133,513	2,314,351,889
Total	9,184,894,382	7,805,248,414

7. Other income

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Other income		
Income from warehouse leasing	13,352,180	1,096,418,350
Other income	40,760,580	120,003,151
Total	54,112,760	1,216,421,501

b) Other income with related parties: Details are presented in Note VIII.2**8. Other expenses**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Administrative fines and late payment of taxes and insurance	-	3,500,000
Inventory processing	217,965,697	203,238,720
Other expenses	46,765,344	56,067,633
Total	264,731,041	262,806,353

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***9. Current corporate income tax expense**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Total accounting profit before tax	(2,996,829,699)	(1,758,081,163)
Non-deductible expenses when calculating corporate income tax	2,006,572,000	1,687,663,140
Other adjustments (if any)	-	-
Losses carried forward and offset against operating profits and losses	-	-
Corporate income taxable income	(990,257,699)	(70,418,024)
Current corporate income tax rate	20%	20%
Corporate income tax expense calculated on current taxable income	-	-

10. Production cost by nature

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Raw materials and consumables	63,893,570,755	64,255,613,088
Labour cost	14,530,025,149	11,793,040,099
Depreciation of fixed assets	11,061,643,410	10,979,234,552
Out-sourced services	2,537,775,095	2,167,072,124
Other monetary expenses	5,004,089,639	4,472,070,421
Total	97,027,104,048	93,667,030,284

11. Basic earnings per share

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Accounting profit after corporate income tax	(2,996,829,699)	(1,758,081,163)
Adjustments of increase or decrease in accounting profit to determine profit or loss allocating to shareholders holding common shares:	-	-
Adjustments of decrease	-	-
Loss allocating shareholders holding common shares	(2,996,829,699)	(1,758,081,163)
Average ordinary shares in circulation for the period	20,000,000	20,000,000
Basic earnings per share	(149.84)	(87.90)

VII. Additional information for items presented in the Interim Cash Flow Statement

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
1. Actual receipt of borrowing amounts in the period		
Proceeds from borrowings under normal agreement	920,000,000	250,000,000
2. Principal amount paid in the period		
Payment of borrowing principal under normal agreement	-	100,000,000

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***VIII. Other information****1. Subsequent events after reporting date**

The Board of General Directors confirms that, in all material respects, there are no unusual events arising after the balance sheet date that affect the financial position and operation of the Company and need to be adjusted or presented on the Interim Financial Statements for the period from 01/01/2025 to 30/6/2025.

2. Transactions and balances with related parties

Related parties of the Corporation include: key members, individuals who are related to key members and other related parties.

List of related parties:

Related parties	Relationship
Vietnam Pharmaceutical Corporation - JSC	Major shareholder
Binh An Developed Investment JSC	Unit receiving contributed capital
Mr Cao Tien Dung	Chairman (Appointed on April 21, 2025), Deputy General Director
Mr. Nguyen Tien Duc	Chairman (Resigned on April 21, 2025)
Mr. Le Tien Dung	Vice Chairman of Board of Management, General Director
Mr. Cao Minh Phuong	Vice Chairman of Board of Management (Appointed on April 21, 2025)
Mr. Cao Quang Hung	Member of Board of Management (Resigned on April 21, 2025)
Mr. Le Hoang Phong	Member of Board of Management (Appointed on April 21, 2025)
Mr. Nguyen Thanh Tung	Member of Board of Management, Deputy General Director
Mr. Cao Viet Hung	Member of Board of Management (Appointed on April 21, 2025)
Mrs. Cao Thuy Tien	Member of Board of Management (Appointed on April 21, 2025)
Mr. Phan Tri Dung	Deputy General Director
Mrs. Nguyen Thi Dieu Thuy	Chief Accountant
Mr. Tran Duc Thao	Assistant to Chairman of the Board of Management (Retired from 01/07/2024)
Mrs. Tran Thi Thu Thuy	Chief Supervisor (Appointed on April 21, 2025)
Mr. Luong Tuan Hoan	Chief Supervisor (Resigned on April 21, 2025)
Mr. Ha Tho	Member of Board of Supervisor (Appointed on April 21, 2025)
Mrs. Nguyen Ngoc Huyen	Member of Board of Supervisor (Appointed on April 21, 2025)
Mrs. Duong Thi Ngoc	Member of Board of Supervisor (Resigned on April 21, 2025)

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)***a) During the period, the Company has entered into its significant transactions with related parties as follows:**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Interest expense		
Mr. Le Tien Dung	31,500,000	31,500,000
Mr. Phan Tri Dung	4,200,000	4,200,000
Mr. Cao Minh Phuong	115,200,000	
Other income (Income from warehouse leasing)		
Vietnam Pharmaceutical Corporation - JSC	-	1,082,001,000

b) Balances with related parties

	30/6/2025 VND	01/01/2025 VND
Other receivables		
Binh An Developed Investment JSC	49,600,314,938	49,600,314,938
Other payables		
Binh An Developed Investment JSC	93,960,000,000	93,960,000,000
Loans		
Mr. Le Tien Dung	750,000,000	750,000,000
Mr. Phan Tri Dung	50,000,000	50,000,000
Mr. Cao Minh Phuong	2,880,000,000	-

c) Remuneration entitled to key management members

Details of the income of key management members in the period as follows:

<u>Name</u>	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Board of Management and Board of Directors 's income	1,159,957,809	1,079,881,362
Mr. Nguyen Tien Duc	172,177,910	216,034,090
Mr. Le Tien Dung	356,568,363	322,530,911
Mr. Phan Tri Dung	204,733,364	182,799,545
Mr. Nguyen Thanh Tung	198,552,909	175,994,544
Mr. Cao Tien Dung	227,925,263	182,522,272
Income of Chief Accountant and Other Management Members	214,660,273	383,681,817
Mrs. Nguyen Thi Dieu Thuy	214,660,273	192,401,817
Mr. Tran Duc Thao	-	191,280,000

NOTES TO THE INTERIM FINANCIAL STATEMENTS (continue)*(These notes are an integral part of and should be read in conjunction with the accompanying Interim Financial Statements.)*

Remuneration of Board of Management	31,000,000	24,000,000
Mr. Cao Tien Dung	7,000,000	6,000,000
Mr. Le Tien Dung	6,000,000	6,000,000
Mr. Cao Minh Phuong	2,000,000	-
Mr. Cao Quang Hung	4,000,000	6,000,000
Mr. Nguyen Thanh Tung	6,000,000	6,000,000
Mrs. Cao Thuy Tien	2,000,000	-
Mr. Le Hoang Phong	2,000,000	-
Mr. Cao Viet Hung	2,000,000	-
Remuneration of Board of Supervisors	14,400,000	14,400,000
Mrs. Tran Thi Thu Thuy	4,800,000	4,200,000
Mr. Luong Tan Hoan	4,000,000	6,000,000
Mr. Ha Tho	1,400,000	-
Mrs. Nguyen Ngoc Huyen	1,400,000	-
Mrs. Duong Thi Ngoc	2,800,000	4,200,000
Total	1,420,018,082	1,501,963,179

3. Comparative information

Comparative figures are the figures of the Interim Financial Statements for the period from 01/01/2024 to 30/6/2024 and the Financial Statements for the year ended 31/12/2024 of Central Pharmaceutical Joint Stock Company No2 reviewed and audited by Vietnam Auditing and Evaluation Co., Ltd.

Hanoi, August 11, 2025

CENTRAL PHARMACEUTICAL JOINT STOCK COMPANY NO2**Prepared by**

Dinh Thi Minh Huong**Chief Accountant**

Nguyen Thi Dieu Thuy**General Director****Le Tien Dung**

CENTRAL PHARMACEUTICAL
JOINT STOCK COMPANY NO2SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 182 /CBTT-DPTU2

Hanoi, August 12, 2025

PERIODIC DISCLOSURE OF FINANCIAL STATEMENTS

To: Hanoi Stock Exchange

Pursuant to the provisions of Clause 3, Article 14 of Circular No. 96/2020/TT-BTC dated November 16, 2020 of the Ministry of Finance guiding disclosures on the stock market, Central Pharmaceutical Joint Stock Company No2 shall disclose information on the financial statements (FS) for the first quarter 2025 to the Hanoi Stock Exchange as follows:

1. Company name:

- Ticker symbol: DP2
- Address: No. 9 Tran Thanh Tong Street, Bach Dang Ward, Hai Ba Trung District, Hanoi.
- Tel: 024 39716579/91: Fax: 024 35251484.
- Email: dopharma@dopharma.com.vn.
- Website: www.dopharma.com.vn _ dopharma.vn

2. Disclosures:

- 2025 Semi-Annual Financial Report

☒ Separate financial statements (The listed company has no subsidiaries and the superior accounting entity has affiliates);

☐ Consolidated financial statements (the listed company has subsidiaries);

☐ Combined financial statements (the listed company has affiliated accounting entities with separate accounting apparatus).

- Cases that require explanation:

+ The auditors gave an opinion that was not an unqualified opinion on the financial statements (for audited financial statements in 2024):

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ The difference between pre- and post-audit profit in the reporting period is 5% or more, transferring from loss to profit or vice versa (for audited financial statements in 2024):



☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

+ Profit after corporate income tax in the income statement of the reporting period changes by 10% or more compared to the same reporting period of the previous year:

☒ Yes

☐ No

Explanatory document where you mark the box "Yes":

☒ Yes

☐ No

+ Profit after tax in the reporting period is a loss, transferring from profit in the same period of the previous year to loss in this period or vice versa:

☐ Yes

☐ No

Explanatory document where you mark the box "Yes":

☐ Yes

☐ No

This information was published on the Company's website on: April 18, 2025: www.dopharma.com.vn _ dopharma.vn



Attachments:

-2025 Semi-Annual Financial Report

- Explanation of financial statements for the first quarter

For the Company

Legal representative/ person authorized to make disclosures
(Signature, full name, position, seal)



Pharmacist Le Tien Dung